Last reviewed · How we verify
Intravenous acetominophen
Intravenous acetominophen is a Small molecule drug developed by The University of Texas Medical Branch, Galveston. It is currently FDA-approved. Also known as: Ofirmev.
At a glance
| Generic name | Intravenous acetominophen |
|---|---|
| Also known as | Ofirmev |
| Sponsor | The University of Texas Medical Branch, Galveston |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (PHASE3)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous acetominophen CI brief — competitive landscape report
- Intravenous acetominophen updates RSS · CI watch RSS
- The University of Texas Medical Branch, Galveston portfolio CI
Frequently asked questions about Intravenous acetominophen
What is Intravenous acetominophen?
Intravenous acetominophen is a Small molecule drug developed by The University of Texas Medical Branch, Galveston.
Who makes Intravenous acetominophen?
Intravenous acetominophen is developed and marketed by The University of Texas Medical Branch, Galveston (see full The University of Texas Medical Branch, Galveston pipeline at /company/the-university-of-texas-medical-branch-galveston).
Is Intravenous acetominophen also known as anything else?
Intravenous acetominophen is also known as Ofirmev.
What development phase is Intravenous acetominophen in?
Intravenous acetominophen is FDA-approved (marketed).
Related
- Manufacturer: The University of Texas Medical Branch, Galveston — full pipeline
- Also known as: Ofirmev
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing